Group 1 - Shandong Mingxiang Biotechnology Co., Ltd. has been established with a registered capital of 10 million yuan, focusing on biomass energy technology services and comprehensive utilization of agricultural and forestry waste [1][2] - The company is co-owned by He Feng Food Co., Ltd. (35% share), Yafang New Ge Feng Agricultural Technology Co., Ltd. (35% share), and Pufang He Guangyuan Animal Health Co., Ltd. (30% share) [3] - The business scope includes cell technology research and application, livestock and fishery feed sales, and animal health monitoring [2][3] Group 2 - The company is located in Gaomi City, Shandong Province, and is registered under the High-Mi City Market Supervision Administration [2] - The operational period of the company is set until July 30, 2025, with no fixed expiration date [2] - The company is classified under the scientific research and technical services industry [2]

He said the "future of Moderna is bright," noting that it now has three approved products and the potential for up to eight more in the next three years. In May, the Food and Drug Administration approved Moderna's third- ever product, a next-generation Covid shot. But Bancel said "this decision was not made lightly." Also in May, Moderna said it will reduce annual operating expenses by about $1.5 billion by 2027. That target adds to cuts that the company previously announced. Moderna will provide another up ...

近日，2024年度第三批"百项亚健康中医调理技术" 名单相关信息公布，天津万古基缘生物技术有限公 司申报的姚清生先生研制的万古基缘植物复合浓缩液的 "营养免疫生物强化亚健康中医调理技术" 在 列。该技术通过了中和亚健康服务中心、百项亚健康中医调理技术评审专家委员会的评审。 中和学［2024］131 号 公开信息显示，天津万古基缘生物技术有限公司是一家研发、生产和销售超级药食同源产品的国际集 团。2009 年其创始人姚清生（王玉山）先生在加拿大独资筹建工厂，2011年12月建成现代化工厂，该 工厂年生产能力可达十几亿美元。天津万古基缘生物技术有限公司注册资金 1 亿元。 据了解，中和亚健康服务中心由国家中医药管理局主管，是国家批准的唯一从事亚健康研究、服务、管 理，构建亚健康服务体系及培养亚健康专业人才的机构。 中和亚健康服务中心 此次技术入选后，相关授权信息同步明确：天津万古基缘生物技术有限公司被授权为天津中和亚健康服 务中心，姚清生先生担任主任。该中心及负责人将承担两项职责，一是在天津的 "亚健康专业调理机 构" 的建设与运营指导和亚健康相关技能培训；二是万古基缘公司在全国的 "亚健康专业调理机构" 的 建 ...

Group 1 - The core viewpoint of the articles emphasizes the support from the Medical Insurance Bureau for the medical device industry, focusing on principles such as "anti-involution," overseas expansion, and differentiated innovation, which are beneficial for high-quality industry development [1] - The collective procurement prices are expected to remain moderate, which will help stabilize and enhance corporate profitability [1] - Policies are anticipated to stimulate innovation and research and development (R&D) among medical device companies, with new product launches likely to create growth opportunities and accelerate domestic substitution [1] Group 2 - As R&D capabilities improve, policies will assist in the global development of Chinese innovative drugs and medical devices, allowing companies to explore international markets [1] - In the pharmaceutical and biotechnology sector, innovative drugs are entering a stage of realization, with significant R&D progress that is not affected by trade wars, continuing to serve as an investment focus [1] - Companies expanding into emerging markets are expected to have substantial growth potential [1] Group 3 - The ChiNext Medical ETF (159377) tracks the ChiNext Medical Index (399275), which can experience daily fluctuations of up to 20% [1] - This index selects listed companies involved in biomedicine and medical devices from the ChiNext market, covering sectors such as innovative drug R&D, biotechnology, and medical services, reflecting the overall performance of related listed companies [1]

韩国总统李在明宣布韩国已与美国“结束关税谈判”，并表示这批3500亿美元的资金“将在促进韩国企业积极进入美国市场方面发挥作用，这些行业都是我们具有优势的行业，例如造船、半导体、电池、生物技术和能源”，其中1500亿美元将用于“造船合作，为韩国企业进入美国造船业提供强有力的支持”，并补充说，“实现互利互惠的结果非常重要，而不仅仅是追求单方面的利益。”外汇交易员 (@myfxtrader):特朗普表示，美韩双方达成一致，美国将对韩国征收15%的关税。同时，美国不会被征收关税。韩国将对美全面开放贸易，接受包括汽车、卡车和农产品在内的美国产品。 ...

Core Insights - South Korea plans to allocate $200 billion of its investments in the U.S. towards sectors such as semiconductors, nuclear power, and biotechnology [1] Group 1 - A total of $350 billion fund from South Korea may be composed of loans, primarily guaranteed loans [1]

韩国总统办公室：2000亿美元的资金将用于芯片、核能、电池和生物技术。 ...

Core Insights - The 2025 "Maker China" Changsha Small and Medium Enterprises Innovation and Entrepreneurship Competition concluded successfully, showcasing projects aimed at key industrial upgrade tracks [1][3] - A series of support measures are expected to be implemented post-competition, combining policies, funding, and services to accelerate the growth of award-winning projects [1][7] Group 1: Competition Overview - The competition featured an "8-minute project presentation + 3-minute expert questioning" format, with evaluations conducted by a panel of industry experts, investment representatives, and company representatives [3] - The awards highlighted significant projects in both the enterprise and entrepreneurial categories, focusing on breakthroughs in the real economy and cutting-edge innovations [3] Group 2: Award-Winning Projects - In the enterprise category, Hunan Gaichuang Rare Earth New Materials Co., Ltd. won first prize for its "High-Purity Metal Scandium and Aluminum Scandium Target Material Preparation Technology," which breaks international monopolies and secures key raw material supplies for 5G communications and satellite chips [3] - Huazhi Biotechnology Co., Ltd. also won first prize for its "Molecular Intelligent Breeding Liquid Phase Chip Development and Application," achieving high precision, low cost, and high efficiency in gene testing [3] - The second prize was awarded to six projects, including Hunan Bizu Biotechnology Co., Ltd. and Hunan Enzhi Measurement and Control Technology Co., Ltd., covering critical fields such as life health and new energy security [3] - The third prize went to twelve projects, including Hunan Xian Sodium Technology Co., Ltd., focusing on national strategic needs and technological breakthroughs [3] Group 3: Entrepreneurial Projects - In the entrepreneurial category, Changsha Wave Function Technology Co., Ltd. won first prize for its "Qihua Technology - Intelligent Temperature Control for Computing Power Infrastructure," which revolutionizes traditional cooling solutions [5] - Changsha Ruixian Technology Co., Ltd. also won first prize for its "Dual Breakthrough in OLED Ultra-Thin Electrode Materials and Processes," addressing industry challenges for high-performance silicon-based OLED chip mass production [5] - Six projects, including Brain Step Technology and Hunan Lurong New Materials Co., Ltd., received second prizes, targeting life health, energy technology, and advanced materials [5] Group 4: Future Prospects - The top 20 projects from the enterprise group and the top 10 from the entrepreneurial group will represent Changsha in the provincial competition, showcasing the city's innovation capabilities on a larger stage [7] - The competition's conclusion is viewed as a starting point for the accelerated growth of quality projects, with plans to enhance the "competition-driven talent and innovation promotion" mechanism [7] - Award-winning projects are expected to transform technology into new productive forces, potentially becoming new engines for high-quality development in Changsha [7]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●交易简要内容：基于公司战略规划需要，公司计划在上海设立华东总部。 经友好协商，公司拟与上海延藜生物技术有限公司（以下简称"上海延藜公司"） 签订房地产租赁合同，公司向上海延藜公司租赁其房地产作为华东总部办公使 用，具体房地产为上海延藜公司从上海春光实业有限公司承租的上海市普陀区泸 定路 276 弄 5 号楼（共 5 层）。其中 1 层部分区域提供公司无偿使用，作为公司 产品体验中心；2 层公司与上海延藜公司无偿共用，用作客户接待区域。第 3、4、 ●至本次关联交易为止，过去 12 个月与同一关联人以及与不同关联人进行 的交易类别相关的关联交易（日常关联交易除外）的累计次数为 2 次：协和干细 胞基因工程有限公司继续委托天津市红磡物业经营管理有限公司负责天津市华 苑 产 业 园 区 梅苑 路 12 号 区 域内 的物 业管 理服务 ，合 同 期 服务 费用 总 计 为 中源济生细胞科技有限公司 25%股权，转让价格为人民币 3,819,575 元。 一、关联交易概 ...

Group 1 - The core viewpoint of the news highlights the strong financial performance of BeiGene, with a significant revenue increase and a positive outlook from Morgan Stanley [1][2] - As of March 31, 2025, BeiGene reported total revenue of $1.117 billion, representing a year-on-year growth of 48.64% [1] - The company achieved a net profit attributable to shareholders of $1.27 million, marking a substantial year-on-year increase of 100.51% [1] Group 2 - BeiGene is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment [2] - The company has a diverse product portfolio, including six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2] - Founded in Beijing in 2010, BeiGene was listed on the NASDAQ Global Select Market in February 2016 and has built a global team of over 1,300 employees as of July 2018 [2]